Evidence map›Paper›PMID 35883550›Full record

ReviewBiomolecules2022

α-Synuclein Conformational Plasticity: Physiologic States, Pathologic Strains, and Biotechnological Applications.

Amanda Li, Cyrus Rastegar, Xiaobo Mao

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Posttranslational Modifications ofPharmacological reviews · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Liquid-liquid phase separation and conformational strains ofFrontiers in molecular neuroscience · 2024
    Review
  10. Novel strategies in Parkinson's disease treatment: a review.Frontiers in molecular neuroscience · 2024
    Review
  11. Article
  12. Synucleinopathies: Intrinsic and Extrinsic Factors.Cell biochemistry and biophysics · 2023
    Article
  13. The Interplay between α-Synuclein and Microglia in α-Synucleinopathies.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amanda LiNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-7408-0272
Cyrus RastegarNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Xiaobo MaoNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-6587-556X
Johns Hopkins University · US

Funding

Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's DiseaseR01AG073291 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2021 to 2025
$3.2M
Heterochronic Blood Exchange Inhibits α?Synucleinopathy through Modulating Plasma Protein's Mediation on Pathological α?Synuclein SpreadingR01AG071820 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2021 to 2025
$2.3M
α-Synuclein strain properties are associated with diagnosis of and progression to Parkinson's disease with dementiaRF1NS125592 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO, ROSENTHAL, LIANA ISA SHAPIRO · 2022 to 2022
$2.1M
Understanding the Mechanism of Pathological alpha-Synuclein TransmissionR01NS107318 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2019 to 2023
$2.0M
Influence of Aging on Pathogenic Alpha-Synuclein Strains and Transmission MechanismK01AG056841 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2017 to 2021
$651k
Chemical Fingerprints of Cognitive Impairment-related alpha-Synuclein Strains using 3D Small Molecule Microarray and Related Therapeutic ApplicationR21NS125559 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2022 to 2022
$450k
NIA NIH HHS K01 AG056841NIA NIH HHS R01 AG071820NIA NIH HHS R01 AG073291NINDS NIH HHS R01 NS107318NINDS NIH HHS R21 NS125559NINDS NIH HHS RF1 NS125592
6 · The paper itself

Abstract

α-Synuclein (αS) is remarkable for both its extensive conformational plasticity and pathologic prion-like properties. Physiologically, αS may populate disordered monomeric, helically folded tetrameric, or membrane-bound oligomeric states. Pathologically, αS may assemble into toxic oligomers and subsequently fibrils, the prion-like transmission of which is implicated in a class of neurodegenerative disorders collectively termed α-synucleinopathies. Notably, αS does not adopt a single "amyloid fold", but rather exists as structurally distinct amyloid-like conformations referred to as "strains". The inoculation of animal models with different strains induces distinct pathologies, and emerging evidence suggests that the propagation of disease-specific strains underlies the differential pathologies observed in patients with different α-synucleinopathies. The characterization of αS strains has provided insight into the structural basis for the overlapping, yet distinct, symptoms of Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. In this review, we first explore the physiological and pathological differences between conformational states of αS. We then discuss recent studies on the influence of micro-environmental factors on αS species formation, propagation, and the resultant pathological characteristics. Lastly, we review how an understanding of αS conformational properties has been translated to emerging strain amplification technologies, which have provided further insight into the role of specific strains in distinct α-synucleinopathies, and show promise for the early diagnosis of disease.

Indexed as

Multiple System AtrophyParkinson DiseasePrionsSynucleinopathiesalpha-SynucleinAnimalsalpha-SynucleinPrionsPMCAprion-likeRT-QuICstrainstetramerα-synucleinα-synucleinopathy

Identifiers

PMID35883550
PMCPMC9313095
OpenAlexW4285732243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.